Table 2.

Summary of exposure and dose-limiting toxicity

Dose level	Number of patients	Number of DLTsa	Median number of cycles (range)
			Paz	Gem
Paz400/Gem1000	6	1b	5.5 (2–17)	5.5 (2–17)
Paz800/Gem1000	3	0	6 (5–12)	6 (5–12)
Paz800/Gem1250	13	1c	4 (1–14)	4 (1–14)

DLT dose-limiting toxicity, Gem gemcitabine, Paz pazopanib

^aObserved during Cycles 1 and 2 during the dose-escalation phase

^bGrade 4 thrombocytopenia

^cGrade 3 fatigue